Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mitsubishi Tanabe Gains Premium Prices For Fingolimod And Telaprevir

This article was originally published in PharmAsia News

Executive Summary

Japan's Chuikyo rewarded the company with better-than-expected NHI listings, but can Mitsubishi Tanabe's sales force shortages help fill demand?

You may also be interested in...



Mitsubishi Tanabe Sees Open Road With Telaprevir Approval And Merck's Boceprevir Discontinued In Japan

TOKYO - Mitsubishi Tanabe Pharma Corp. received a double dose of good news Sept. 26, leading a list of drugs that received marketing approval from Japan's Ministry of Health, Labor and Welfare with in-licensed protease inhibitor telaprevir and oral multiple sclerosis therapy fingolimod

Avastin Recommended For Breast Cancer Approval In Japan; Telaprevir Leads List Of Unanimous Recommendations

TOKYO - Telaprevir and a metastatic breast cancer indication for Avastin (bevacizumab) were among the blanket recommendations for approval by the Second Subcommittee on New Drugs of Japan's Ministry of Health, Labor and Welfare announced late in the day Aug. 25. Avastin's recommendation came just a few weeks after the subcommittee had expressed doubts about the drug's efficacy

FCPA In The China Framework Warrants Special Attention

The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?

Topics

Related Companies

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel